NCT02207790View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy Subjects
Interventions
DRUG

E2609

DRUG

Placebo

E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects

Trial Locations (1)

Unknown

Glendale

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02207790 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects | Biotech Hunter | Biotech Hunter